Stroke worry and QoL issues sway US panel against Abiomed's artificial heart
This article was originally published in Clinica
Executive Summary
The introduction in the US of a total artificial heart (TAH) as a last-ditch treatment for the most sick cardiac patients needs to be put on hold until various safety questions are answered, a deeply divided FDA advisory committee on June 23.
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.